Skip to main content
SpringerLink
Log in

Neuropharmacology of Emesis and Its Relevance to Antiemetic Therapy

Consensus and Controversies

  • Conference paper
Perugia Consensus Conference on Antiemetic Therapy

Abstract

Recent great advances in the neuropharmacology of the emetic pathways have led to better therapy and improved insight into pathophysiological processes in patients undergoing chemo- and radiotherapy. This article gives an overview of the area, outlines current controversies, and makes recommendations for future clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Andrews PLR (1996) The mechanism of emesis induced by chemotherapy and radiotherapy, pp 3–24. In: Tonato M (ed) Anti-emetics in the supportive care of patients. ( ESO monograph) Springer, Berlin Heidelberg New York

    Google Scholar 

  2. Andrews PLR, Bhandari PB (1993) Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology 32: 799–806

    Article  PubMed  CAS  Google Scholar 

  3. Andrews PLR, Davis CJ (1995) The physiology of emesis induced by anti-cancer therapy. In: Reynolds J, Andrews PLR, Davis CJ (eds) Serotonin and the scientific basis of anti-emetic therapy. Oxford Clinical Communications, Oxford, pp 25–49

    Google Scholar 

  4. Andrews PLR, Whitehead SA (1990) Pregnancy sickness. News Physiol Sci 5: 5–10

    CAS  Google Scholar 

  5. Andrews PLR, Rapeport G, Sanger GJ (1988) Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 9: 334–341

    Article  PubMed  CAS  Google Scholar 

  6. Andrews PLR, Bhandari PB, Davis CI (1992) Plasticity and modulation of the emetic reflex. In: Bianchi AL, Grelot L, Miller AD, King GI (eds) Mechanisms and control of emesis. John Libbey Eurotext, vol 223, INSERM, Paris, pp 275–284

    Google Scholar 

  7. Andrews PLR, Quan V, Ogg CS (1995) Ondansetron for symptomatic relief in terminal uraemia. Nephrol Dial Transplant 10: 40

    Google Scholar 

  8. Beattie WS, Lindblad Z, Buckley ND, Forrest JB (1991) The incidence of postoperative nausea and vomiting in women undergoing laparoscopy is influenced by the day of the menstrual cycle. Can J Anaesth 38: 298–302

    Article  PubMed  CAS  Google Scholar 

  9. Bruera E, Catz Z, Hooper R, Lentle B, MacDonald W (1987) Chronic nausea and anorexia in advanced cancer patients: a possible role for autonomic dysfunction. J Pain Symptom Manage 2: 19–21

    Article  PubMed  CAS  Google Scholar 

  10. Costall B, Domeney AM, Naylor RJ, Tattersall FD (1986) 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 25: 959–961

    Google Scholar 

  11. Costall B, Naylor RJ, Owera-Atepo J, Tattersall FD (1989) The responsiveness of the ferret to apomorphine-induced emesis. Br J Pharmacol 96: 329 P

    Google Scholar 

  12. Cubeddu LX, Alfieri AB, Hoffmen IS (1995) Clinical evidence for the involvement of serotonin in acute cytotoxic-induced emesis. In: Reynolds J, Andrews PLR, Davis CJ (eds) Serotonin and the scientific basis of anti-emetic therapie. Oxford Clinical Communications, Oxford pp 142–149

    Google Scholar 

  13. Cubeddu LX, O’Connor DT, Hoffmann I, Palmer RI (1995) Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies. Br J Cancer 72: 1033–1038

    Article  PubMed  CAS  Google Scholar 

  14. Gardner CJ, Twissel DJ, Dale TJ, Gale JD, Jordan CC, Kilpatrick GJ, Bountra C, Ward P (1995) The broad spectrum anti-emetic activity of the novel non-peptide tachykinin NK-1 receptor antagonist GR 203040. Br J Pharmacol 116: 158–163

    Google Scholar 

  15. Gonsalves S, Watson JW, Ashton C (1996) Broad spectrum antiemetic effect of CP-122 721, a tachykinin NK1 receptor antagonist, in ferrets. Eur J Pharmacol 305: 181–185

    Article  PubMed  CAS  Google Scholar 

  16. Grelot L, Milano S, Le Stunff H (1995) Does 5HT play a role in the delayed phase of cisplatin-induced emesis? In: Reynolds J, Andrews PLR, Davis CJ (eds) Serotonin and the scientific basis of anti-emetic therapy. Oxford Clinical Communications, Oxford, pp 181–191

    Google Scholar 

  17. Kleinerman KB, Deppe SA, Sargent AI (1993) Use of ondansetron for control of projectile vomiting in patients with neurosurgical trauma: two case reports. Ann Pharmacother 27: 566–568

    PubMed  CAS  Google Scholar 

  18. Lucot JB, Crampton GH (1989) 8–0H-DPAT suppresses vomiting in the cat elicited by motion cisplatin or xylazine. Pharmacol Biochem Behav 33: 627–631

    Google Scholar 

  19. Matsuki N, Torii Y, Saito H (1993) Effects of iron and desferrioxamine on cisplatin-induced emesis: further evidence for the role of free radicals. Eur J Pharmacol [Environ Toxicol Pharmacol] 248: 329–331

    Article  CAS  Google Scholar 

  20. Miller AD, Jakus J, Nonaka S (1994) Plasticity of emesis to a 5HT-3 agonist: effect of visceral nerve cuts. Neuroreport 5: 986–988

    Article  PubMed  CAS  Google Scholar 

  21. Miller AD, Rowley HA, Roberts PL, Kucharczyk J (1996) Human cortical activity during vestibular and drug-induced nausea detected using MSI. Ann NY Acad Sci 781: 670–672

    Article  PubMed  CAS  Google Scholar 

  22. Miner WJ, Sanger GJ (1986) Inhibition of cisplatin induced vomiting by selective 5hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88: 497–499

    PubMed  CAS  Google Scholar 

  23. Minton AU, Swift N, Lawlor R, Mant C, Henry J (1995) Ipecacuanha-induced emesis–a human model for testing antiemetic drug activity. Clin Pharmacol Ther 54: 53–57

    Article  Google Scholar 

  24. Okada F, Saito H, Matsuki N (1995) Blockade of motion-and cisplatin-induced emesis by a 5-HT2 receptor agonist in Suncus murinus. Br J Pharmacol 114: 931

    PubMed  CAS  Google Scholar 

  25. Racke K, Schworer H, Kilbinger H (1995) The pharmacology of 5-HT release from enterochromaffin cells. In: Reynolds J, Andrews PLR, Davis CJ (eds) Serotonin and the scientific basis of anti-emetic therapy. Oxford Clinical Communications, Oxford, pp 84–89

    Google Scholar 

  26. Reed MD, Marx CM (1994) Ondansetron for treating nausea and vomiting in the poisoned patient. Ann Pharmacother 28: 331–333

    PubMed  CAS  Google Scholar 

  27. Reynolds DJM, Barber NA, Grahame-Smith DG, Leslie RA (1991) Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: the effect of cervical vagotomy and the anti-emetic 5HT-3 receptor antagonist granisetron (BRL43694). Brain Res 565: 321–236

    Article  Google Scholar 

  28. Roila F, Tonato M, Basurto C (1987) Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin treated cancer patients, a randomized double-blind trial of the Italian oncology group for clinical research. J Clin Oncol 5: 141–149

    PubMed  CAS  Google Scholar 

  29. Rub R, Andrews PLR, Whitehead SA (1992) Vomiting: incidence, causes, ageing and sex. In: Bianchi AL, Grelot L, Miller AD, King GI (eds) Mechanisms and control of emesis. (John Libbey Eurotext, vol 223 ) INSERM, Paris

    Google Scholar 

  30. Rudd JA, Naylor RJ (1993) The effect of 5-HT1A receptor ligands on copper sulphate-induced emesis in the ferret. Br J Pharmacol 100: 99 P

    Google Scholar 

  31. Rudd J, Naylor RJ (1994) Effects of 5HT-3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology 33: 1607–1608

    Article  PubMed  CAS  Google Scholar 

  32. Rudd JA, Naylor RJ (1996) An interaction of ondansetron and dexamethasone antagonising cisplatin-induced acute and delayed emesis in the ferret. Br J Pharmacol 118: 209–214

    PubMed  CAS  Google Scholar 

  33. Rudd JA, Jordan CC, Naylor RJ (1996) The action of the NK1 tachykinin receptor antagonist CP99 994, in antagonising the acute and delayed emesis induced by cisplatin in the ferret. Br J Pharmacol 119: 931–936

    PubMed  CAS  Google Scholar 

  34. Schwörer H, MAnke H, Stockmann F (1995) Treatment diarrhea in carcinoid syndrome with ondansetron, tropisetron and clonidine. Am J Gastroenterol 90: 645–648

    PubMed  Google Scholar 

  35. Scott RH, Woods AJ, Lacey MJ, Fernando D, Crawford JH, Andrews PLR (1995) An electrophysiological investigation into the effects of cisplatin and the protective effects of dexamethasone on cultured dorsal root ganglion neurones from neonatal rats. NS Arch Pharmacol 352: 247–255

    CAS  Google Scholar 

  36. Tattersall FD, Rycroft W, Hill RG, Hargreaves RJ (1994) Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin-1 receptor antagonist CP-99 994. Neuropharmacology 33: 259–260

    Article  PubMed  CAS  Google Scholar 

  37. Tonini M (1995) 5HT4 receptor involvement in emesis. In: Reynolds J, Andrews PLR, Davis CJ (eds) Serotonin and the scientific basis of anti-emetic therapy. Oxford Clinical Communications, Oxford, pp 192–199

    Google Scholar 

  38. Watson JW, Gonsalves SF, Fossa AA, McLean S, Seeger T, Obach S, Andrews PLR (1995) The anti-emetic effects of CP-99 994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol 115: 84–94

    PubMed  CAS  Google Scholar 

  39. Whitehead SA, Holden WA, Andrews PLR (1992) Pregnancy sickness. In: Bianchi AL, Grelot L, Miller AD, King GL (eds) Mechanisms and control of emesis. Libbey Eurotext, pp 297–306 (Colloque INSERM vol 223 )

    Google Scholar 

Download references

Authors
  1. P. L. R. Andrews
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. J. Naylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. A. Joss
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Ochsner Cancer Institute, 1514 Jefferson Highway, 70121-2483, New Orleans, LA, USA

    Richard J. Gralla

  2. Oncologia Medica, Policlinico Monteluce, Via Brunamonti, 06122, Perugia, Italy

    Maurizio Tonato  & Fausto Roila  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Andrews, P.L.R., Naylor, R.J., Joss, R.A. (1998). Neuropharmacology of Emesis and Its Relevance to Antiemetic Therapy. In: Gralla, R.J., Tonato, M., Roila, F. (eds) Perugia Consensus Conference on Antiemetic Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72137-3_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72137-3_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-72139-7

  • Online ISBN: 978-3-642-72137-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation